AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

Shots:

  • The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation
  • The P-III PROfound study resulted in meeting its 1EPs i.e, improvement in radiographic PFS in men with mCRPC selected for BRCA1/2 or ATM gene mutations, safety & tolerability profiles were consistent with the previous study 
  • Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2. AstraZeneca and MSD are also evaluating Lynparza for prostate cancer and as a 1L therapy in ongoing P-III PROpel study in combination with abiraterone for mCRPC

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Life Sciences IP Review